Arterial hypertension in gout patients: Pathogenesis bases, clinical value, diagnosis

Markelova E.I., Eliseyev M.S., Barskova V.G.

Abstract


Cardiovascular diseases (CVD) caused by vascular atherosclerotic lesion are the leading cause of death in gout patients. Analysis of the data available in the literature has indicated that monitoring blood pressure and target organ damage thoroughly serves as the basis for the prevention of CVD and cardiovascular catastrophes in patients with gout.

Keywords


gout; cardiovascular diseases; arterial hypertension

Full Text:

PDF (Russian)
References References

Насонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры — научно обоснованное требование улучшения трудового и жизненного прогноза больных. Науч.-практ. ревматол. 2000; 1: 5—7.

Kuo C.F., Yu K.H., See L.C. et al. Elevated risk of mortality among gout patients: a comparison with the National Population in Taiwan. Joint Bone Spine 2011; 78(6): 577—80.

Krishnan E., Svendsen K., Neaton J.D. et al. MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout. Arch Int Med 2008; 168(10): 1104—10.

Fang J., Alderman M. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971—1992. National Health and Nutrition Examination Survey. JAMA 2000; 238: 2404—10.

Freedman D.S., Willamson D.F., Gunter E.W. et al. Relation of serum uric acid to mortality and ishemic heart disease. The NHANES 1 Epidemiologic Follow-up Study. Am J Epidemiol 1995; 141(7): 637—44.

Brand F.N., McGee D.L., Kannel W.B. et al. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol 1985; 121: 11.

Niskanen L.K., Laaksonen D.E., Nyyssonen K. et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Int Med 2004; 164: 1546.

Барскова В.Г., Ильиных Е.В., Елисеев М.С. и др. Кардиоваскулярный риск у больных подагрой. Ожирение и метаб. 2006; 3(8): 40—4.

Елисеев М.С., Барскова В.Г. Нарушения углеводного обмена при подагре: частота выявления и клинические особенности. Тер. арх. 2010; 5: 50—4.

Kuo C.F., See L.S., Luo S.F. et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology 2010; 49: 141—6.

Kuzell W.C., Schaffarzick R.W., Naugler W.E. et al. Some observations on 520 gouty patients. J Chron Dis 1995; 2,645—69.

Vazguez-Mellado J., Garsia C.G., Vazguez S.G. et al. Metabolic syndrome and ischemic heart disease in gout. J Clin Rheumatol 2004; 10 (3); 105—9.

Weiss T.E., Segaloff A. Gouty Arthritis and Gout. Springfield, Illinois: Thomas, 1959; 7.

Wyngaarden J.B., Kelley W.N. Gout and hyperuricemia. New York: Grune & Stratton, 1976; 512.

Eliseev M.S., Barskova V.G., Nassonova V.A. et al. Insulin resistance syndrome in patients with gout and its influence on uric acid concentration and severity of arthritis. Ann Rheum Dis 2006; 65(Suppl II): 432.

Cannon P.J., Stason W.B., Demartini F.E. et al. Hyperuricemia in primary and renal hypertension. N Eng J Med., 1966; 275: 457—64.

Kinsey D., Walther R., Sise H.S. et al. Incidence of hyperuricemia in 400 hypertensive subjects. Circulation 1961; 24: 972—3.

Verdecchia P., Schillaci G., Reboldi G. et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072—8.

Krishnan E., Baker J.F., Furst D.E. et al. Gout and risk of acute myocardial infarction. Arthr Rheum 2006; 54(8)2688—96.

Mahomed F.A. On chronic Bright's disease, and its essential symptoms. Lancet 1879; 1: 399—401.

Haig A. On uric acid and arterial tension. BMJ 1889; 1: 288—91.

Huchard H. Allgemeine Betrachtungen ü ber die Arteriosklerose. Klin Med Berlin 1909; 5: 1318—21.

Mikkelsen W.M., Dodge H.J., Valkenburg H. The distribution of serum uric acid values in a population unselected as to gout or hyperuricemia. Tecumseh, Michigan 1959—1960. Am J Med 1965; 39: 242—51.

Bulpitt C.J. Serum uric acid in hypertensive subjects. Brit Heart J 1975; 37: 1210—5.

Wallace S.L. Gout and hypertension. Arthr Rheum 1975; 18: 721—3.

The Bogalusa Heart Study: 20 th Anniversary Symposium. Am J Med Sci 1995; 310(Suppl 1): 1—138.

Alper A.B. Jr, Chen W., Yau L. et al. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension 2005; 45: 34—8.

Sundström J., Sullivan L., DAgostino R.B. et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45(1): 28—33.

Selby J.V., Friedman G.D., Quesenberry C.P. Jr. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990; 131,1017—27.

Jossa F., Farinaro E., Panico S. et al. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 1994; 8: 677—81.

Taniguchi Y., Hayashi T., Tsumura K. et al. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens 2001; 19(7): 1209—15.

Choi H.K., Atkinson K., Karlson E.W. et al. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Int Med 2005; 165(7): 742—8.

Johnson R.J., Kang D.-N., Feig D. et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183—90.

Johnson R.J., Rodriguez-Iturbe B., Kang D.H. et al. A unifying pathway for essential hypertension. Am J Hypertens 2005; 18: 431—40.

Nakagawa Т., Mazzali M., Kang D.-H. et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003; 23: 2—7.

Mazzali M., Hughes J., Kim Y.G. et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38(5); 1101—6.

Mazzali M., Kanellis J., Han L. et al. Hyperuricemia induces a primary renal arte-riolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 6: 991—7.

Masuo K., Kawaguchi H., Mikami H. et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42: 474—80.

Feig D.I., Nakagawa T., Karumanchi S.A. et al. Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004; 66: 281—7.

Messerli F.H., Frohlich E.D., Dreslinski G.P. et al. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Arch Int Med 1980; 93: 817—21.

Puig J.G., Ruilope L.M. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999; 17: 869—72.

Leyva F., Anker S., Swan J.W. et al. Serum Uric Acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 8: 858—65.

Friedl H.P., Till G.O., Trentz O. et al. Role of oxygen radicals in tourniquet related ischemia reperfusion injury of human patients. Klin Wochenschr 1991; 69: 1109—12.

Johnson R.J., Herrera-Acosta J., Schreiner G.F. et al. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002; 346: 913—23.

Saito I., Saruta T., Kondo K. et al. Serum uric acid and the renin-angiotensin system in hypertension. J Am Geriat Soc 1978; 26: 241—7.

Насонова В.А., Елисеев М.С., Барскова В.Г. Влияние возраста на частоту и выраженность признаков метаболического синдрома у больных подагрой. Совр. ревматол. 2007; 1: 31—6.

Кардиология: Национальное руководство. Под ред. Ю.Н. Беленкова, Р.Г. Оганова. М.: ГОЭТАР-Медиа, 2007; 1232 с.

Modan M., Halkin H., Almog S. et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809—17.

Pollare Т., Lithell H., Berne С. Insulin resistance is a characteristic feature of primary hypertension independant of obesity. Metabolism 1990; 39: 167—74.

Ferrannini E., Buzzigoli G., Bonadonna R. et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350—7.

DeFronzo R.A., Tobin J., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: 214—23.

Ferrannini E., Natali A. Essential hypertension, metabolic disorders, and insulin resistance. Am Heart J 1991; 121: 1274—82.

Julius S., Jamerson K., Mejia A. et al. The association of borderline hypertension with target organ changes and higher coronary rise: Tecumseh Blood Pressure Study. JAMA 1990; 264: 354—8.

Ferrari P., Weidmann P., Shaw S.G. et al. Altered insulin sensitivity, hyperinsulinemia and dyslipidemia in individuals with a hypertensive parent. Am J Med 1991; 91: 589—96.

Facchini F., Chen Y.D., Clinkeingbeard C. et al. Insulin resistance, hyperinsulinemia, and dyslipidemia in non obese individuals with family history of hypertension. Am J Hypertens 1992; 5: 694—9.

Allemann Y., Horber F.F., Colombo M. et al. Decreased insulin sensitivity in normotensive offspring of hypertensive parents precedes gain or redistribution of body fat. Lancet 1993; 341: 327—31.

Marchesi E., Perani G., Falaschi F. et al. Metabolic rise factors in white coat hypertensives. J. Hum. Hypertens 1994; 8: 475—9.

Marigliano A., Tedde R., Sechi L.A. et al. Insulinemia and blood pressure: relationship in patients with primary and secondary hypertension, and with or without glucose metabolism impalement. Am J Hypertens 1990; 3: 521—6.

Skarfors E.T., Lithell H.O., Selinus I. Rise factors for the development of hypertension: a 10-year longitudinal study in middleaged men. J Hypertens 1991; 9: 217—37.

Haffner S.M., Ferrannini E., Hazuda H.P. et al. Clustering of cardiovascular rise factors in confirmed prehyper-tensive individuals. Hypertension 1992; 20: 38—45.

Зимин Ю. В. Инсулинорезистентность, гиперинсулинемия и артериальная гипертония. Кардиология 1996; 11: 80—92.

Соколов E. Особенности метаболизма у больных ишемической болезнью сердца по данным инсулиновой пробы. Кардиология 1990; 7: 43—6.

Ferrannini E., De Fronzo R.A. The association of hypertension, diabetes and obesity: A review. J Nephrol 1989; 1: 3—15.

Modan M., Halkin H. Hyperinsulinemia or increased sympathetic drive as a links for obesity and hypertension. Diabet Care 1991; 14(6): 470—87.

Daly P.A., Landsberg L. Hypertension in obesity and NID-DM: role of insulin and sympathetic nervous system. Diabetes Care 1991; 14: 240—8.

Rowe J.W., Young J.В., Minaker K.L. et al. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981; 30: 219—23.

Mahnensmith R.L., Aronson P.S. The plasma membrane sodium-hydrogen axchanger and its role in physiological and pathophysiological process. Circ Res 1985; 56: 773—88.

Длусская И.Г., Стрюк Р.И., Бобровницкий И.П. и др. К вопросу о связи между адренорецепцией клеточных мембран и инсулинемией у больных гипертонической болезнью при лечении антагонистами кальция. Эксперим. и клин. фармакол. 1995; 6: 49—51.

Шестакова М.В. Проблема артериальной гипертонии при сахарном диабете. Кардиология 1999; 6: 59—64.

Rabmouni K., Correia M.L.G., Hayens W.G. el al. Obesety-associated hypertension. New insights into mechanisms. Hypertension 2005; 45: 9—14.

Мамедов М.И., Метельская В.А., Перова Н.В. Метаболический синдром: пути реализации атеротромбогенного потенциала. Кардиология 2000; 40(2): 83—9.

Стрюк Р.И., Токмачев Ю.К., Длусская И.Г. и др. Функциональное состояние клеточных мембран у больных ГБ с гипер- и нормоинсулинемией. Кардиология 1997; 10: 34—7.

Huot S.J., Aronson P.S. Na+ — Н+-exchanger and its role in essential hypertension and diabetes mellitus. Diabet Care 1991; 14: 521—35.

Петров В.В., Бритов А.Н., Константинов Е.Н. и др. Зависимость между артериальным давлением и скоростью Na+ — Li+-противотранспорта в репрезентативной подвыборке из популяции жителей Москвы. Тер. арх. 1990; 4: 81—5.

Linas S.L. The role of potassium in the pathogenesis and treatment of hypertension. Kidney Int 1991; 39: 771—86.

Schefer W., Prieben J., Mannhold R. et al. Са2+ — Mg2+ -ATPase activity of human red cell in healthy and diabetic volunteers. Klin Wochenschr 1987; 65: 17—21.

Pfeifle В., Ditschuneit H. Effect of insulin on groth of cultured human arterial smooth muscle cells. Diabetologia 1981; 20: 155—8.

Рязанов А.С., Смирнова М.Д., Юренев А.П. Гипертрофия миокарда левого желудочка. Вопросы патогенеза. Тер. арх. 2000; 2: 72—7.

Brunds M.W., Hall J.E. Hyperinsulinemia and hypertonia. NMCD 1993; 3: 155—7.

Sowers J.R., Lester M.A. Diabetes and cardiovascular disease. Diabet Care 1999; 22(Suppl 3): 14—20.

Choi H.K., Atkinson K., Karlson E.W. et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. New Engl J Med 2004; 350: 1093—103.

Culleton B.F., Larson M.G., Kannel W.B. et al. Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study. Ann Int Med 1999; 131: 7—13.

Mancia G., de Backer G., Dominiczak A. et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESC). J Hypertens 2007; 25(6): 1105—87.

Stepniakowski K.T., Goodfrreind T.L., Eagn B.M. Fatty acids enhance vascular alpha-adrenergic sensitivity. Hypertension 1995; 25: 774—8.

Fraze E., Donner C.C., Swislocki A.L.M. et al. Ambient plasma free fatty acid concentration in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrin Metab 1985; 61: 807—11.

Caro J.F., Kolaczynski J.W., Nyce M.R. et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996; 20i: 159—61.

Segal K.R., Landt M., Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996; 45: 988—91.

Filer J.S. Leptin resistance and obesity. Presented at the 60th Scientific Sessions of the american diabetes association, 2000, San-Antonio, Texas.

Yamagishi S.I., Edelstein D., Du X.L. et al. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001; 276(27): 25096—100.

Quehenberger P., Exner M., Sunder-Plassmann R. et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res 2002; 90: 711—8.

Shin H.J., Oh J., Kang S.M. et al. Leptin induces hypertrophy via p38 mitogen-activated protein kinase in rat vascular smooth muscle cells. Biochem. Biophys Res Commun 2005; 329: 18—24.

Parhami F., Tintut Y., Ballard A. et al. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2001; 88: 954—60.

Nakata M., Yada T., Soejima N. et al. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999; 48: 426—9.

Söderberg S., Ahren В., Jansson J.H. et al. Leptin is associated with increased risk of myocardial infarction. J Int Med 1999; 246(4): 409—18.

Söderberg S., Ahren В., Stegmayr В. Leptin is risk market for first-ever hemorrhagic stroke in population-based cohort. Stroke 1999; 30(2): 328—37.

Narkiewicz K., Somers V.К., Mos L. et al. An independent relationship between plasma leptin and heart rate in untreated patients with essential hypertension. J Hypertens 1999; 17: 245—9.

Чазова И.Е., Мычка В.Б., Сергиенко В.Б. и др. Возможности применения β-блокаторов у больных метаболическим синдромом. Артер. гипертенз. 2002; 6(8): 202—5.

Российское медицинское общество по артериальной гипертонии. Диагностика и лечение артериальной гипертензии. Российские рекомендации (4-й пересмотр). Системные гипертензии 2010; 3: 5—33.

Vakili В., Okin P., Devereux R. Prognostic implications of left ventricular hypertrophy. Am Hear J 2001; 141: 334—41.

Mathew J., Sleight P., Lonn E. et al. Reduction of cardiovascular risk by regression of elecrocardiographic markers of left ventricular hypertrophy by the angiotensin enzyme inhibitor, ramipril. Circulation 2001; 104: 1615—21.

Мычка В.Б., Горностаев В.В., Шикина Н.Ю. и др. Артериальная гипертония и ожирение. Gons med (приложение) 2001; 2: 17—22.

Gottdienner J.S., Reda D.J., Materson B.J. et al. Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. J Am Coll Cardiol 1994; 24: 1492—8.

Campo C., Ruilope L.M., Segura J. et al. Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension. Blood press 2003; 12: 277—83.

Viazzi F., Parodi D., Leoncini G. et al. Serum uric acid and target organ damage in primary hypertension. Hypertension 2005; 45: 991—6.

Cuspidi C., Valerio C., Sala C. et al. Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia. Am J Hypertens 2007; 20: 678—85.

Dahlof В., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995—1003.

Kuo C.-F., Yu K.-H., Luo S.-F. et al. Role of uric acid in the link between arterial stiffness and cardiac hypertrophy: a crosssectional study. Rheumatology (Oxford) 2010; 49(6): 1189—96.

Levy B.I. Microcirculation in hypertension: a new target for treatment? Circulation 2001; 104(6): 735—40.

Struijker Boudier H.A.J. Hypertension and the microcirculation. In: Kaplan N., ed. Hypertension, microcirculation and end organ damage. London. Lippincott Williams & Wilkins 2002; 49—55.

Baumbach G.L., Heistad D.D. Remodeling of cerebral arterioles in chronic hypertension. Hypertension 1989; 13: 968—72.

Sanchez-Lozada L.G., Tapia E., Avila-Casado C. et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol 2002; 283: 1105—10.

Waring W.S., Webb D.J., Maxwell S.R.J. et al. Effect of local hyperucemia on endothelial function in the human forearm vascular bed. Br J Clin Pharmacol 2000; 49: 511.

Rao G.N., Corson M.A., Berk B.C. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991; 266: 8604—8.

Iribarren C., Folsom A.R., Eckfeldt J.H. et al. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study: Atherosclerosis Risk in Communities. Stroke 1999; 29: 635—9.

Baker J.F., Krishnan E., Chen L. et al. Serum uric acid and cardiovascular disease: recent development, and where do they leave us? Am J Med 2005; 118: 816—26.

Coulard C., Bergeron V. Postprandial triglyceride response in visceral obesity in men. Diabetes 1998; 47: 953—60.

Lago F., Dieguez C., Gomez-Reino J. et al. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheum 2007; 3(12): 716—24.

Asia Pacific Cohort Studies Collaboration Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation 2005; 112: 3384—90.

Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937—52.

Ильина А.Е., Барскова В.Г., Насонов Е.Л. Подагра, гиперурикемия и кардиоваскулярный риск. Науч.-практ. ревматол. 2009; 1: 56—62.

Walker W., Neaton J.D., Cutler J.A. et al. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA 1992; 268: 3085—91.

MacMahon S., Peto R., Cutler J. et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765—74.

Чазова И.Е., Ратова Л.Г. Роль суточного мониторирования артериального давления в оценке эффективности антигипертензивной терапии (Результаты суточного мониторирования артериального давления в программе КЛИП-АККОРД). Cons. med. 2007; 1(прил): 18—26.

Sega R., Trocino G., Lanzarotti A. et al. Alterations of cardiac structure in patients with isolated office, ambulatory or home hypertension. Data from the general PAMELA population. Circulation 2001; 104: 1385—92.

Verdecchia P., Clement D., Fagard R. et al. Blood Pressure Monitoring. Task force III: Target-organ damage, morbidity and mortality. Blood Press Monit 1999; 4: 303—17.

Benetos A., Safar M., Rudnichi A. et al. Pulse pressure. A predictor of long-term car diovascular mortality in a French male population. Hypertension 1997; 30: 1410—5.

White W. Analysis of ambulatory blood pressure data in antihypertensive drug trials. J Hypertens 1991; 9: 27—32.

Fratolla A., Parati G., Cuspidi С. et al. Prognostic value of 24-hour pressure variability. J Hypertens 1993; 11: 1133—7.

Kario К., Pickering T.G., Umeda Y. et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives. A prospective study. Circulation 2003; 107: 1401—6.

Levy D., Garrison R.J., Savage D.D. et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322(22): 1561—6.

Reichek N., Devereux R.B. Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation 1981; 63: 1391—8.




DOI: http://dx.doi.org/10.14412/1996-7012-2012-759

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)